Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $16.1 million.

  • Mirum Pharmaceuticals' Cash from Financing Activities rose 31667.1% to $16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.5 million, marking a year-over-year increase of 15808.57%. This contributed to the annual value of $17.7 million for FY2024, which is 9474.18% down from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported Cash from Financing Activities of $16.1 million as of Q3 2025, which was up 31667.1% from $8.7 million recorded in Q2 2025.
  • Over the past 5 years, Mirum Pharmaceuticals' Cash from Financing Activities peaked at $207.1 million during Q3 2023, and registered a low of -$329000.0 during Q4 2022.
  • In the last 5 years, Mirum Pharmaceuticals' Cash from Financing Activities had a median value of $6.6 million in 2021 and averaged $29.9 million.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Cash from Financing Activities surged by 26354800.0% in 2021, and later plummeted by 15349.59% in 2022.
  • Mirum Pharmaceuticals' Cash from Financing Activities (Quarter) stood at $615000.0 in 2021, then tumbled by 153.5% to -$329000.0 in 2022, then soared by 640.12% to $1.8 million in 2023, then skyrocketed by 200.51% to $5.3 million in 2024, then skyrocketed by 201.42% to $16.1 million in 2025.
  • Its Cash from Financing Activities was $16.1 million in Q3 2025, compared to $8.7 million in Q2 2025 and $6.4 million in Q1 2025.